Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)

Immunocompromised patients are at high risk of invasive fungal infections (IFI), in particular those with haematological malignancies undergoing remission-induction chemotherapy for acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) and recipients of allogeneic haematopoietic stem cell...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Mellinghoff, Sibylle Christiane (VerfasserIn) , Buchheidt, Dieter (VerfasserIn) , Giesen, Nicola (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2018
In: Annals of hematology
Year: 2018, Jahrgang: 97, Heft: 2, Pages: 197-207
ISSN:1432-0584
DOI:10.1007/s00277-017-3196-2
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1007/s00277-017-3196-2
Verlag, Volltext: https://doi.org/10.1007/s00277-017-3196-2
Volltext
Verfasserangaben:Sibylle C. Mellinghoff, Jens Panse, Nael Alakel, Gerhard Behre, Dieter Buchheidt, Maximilian Christopeit, Justin Hasenkamp, Michael Kiehl, Michael Koldehoff, Stefan W. Krause, Nicola Lehners, Marie von Lilienfeld-Toal, Annika Y. Löhnert, Georg Maschmeyer, Daniel Teschner, Andrew J. Ullmann, Olaf Penack, Markus Ruhnke, Karin Mayer, Helmut Ostermann, Hans-H. Wolf, Oliver A. Cornely

MARC

LEADER 00000caa a2200000 c 4500
001 1584374500
003 DE-627
005 20230427161327.0
007 cr uuu---uuuuu
008 181123s2018 xx |||||o 00| ||eng c
024 7 |a 10.1007/s00277-017-3196-2  |2 doi 
035 |a (DE-627)1584374500 
035 |a (DE-576)514374500 
035 |a (DE-599)BSZ514374500 
035 |a (OCoLC)1341024277 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Mellinghoff, Sibylle Christiane  |d 1990-  |e VerfasserIn  |0 (DE-588)112248822X  |0 (DE-627)875699855  |0 (DE-576)481342443  |4 aut 
245 1 0 |a Primary prophylaxis of invasive fungal infections in patients with haematological malignancies  |b 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)  |c Sibylle C. Mellinghoff, Jens Panse, Nael Alakel, Gerhard Behre, Dieter Buchheidt, Maximilian Christopeit, Justin Hasenkamp, Michael Kiehl, Michael Koldehoff, Stefan W. Krause, Nicola Lehners, Marie von Lilienfeld-Toal, Annika Y. Löhnert, Georg Maschmeyer, Daniel Teschner, Andrew J. Ullmann, Olaf Penack, Markus Ruhnke, Karin Mayer, Helmut Ostermann, Hans-H. Wolf, Oliver A. Cornely 
264 1 |c 2018 
300 |a 11 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Published online 7 December 2017 
500 |a Gesehen am 23.11.2018 
520 |a Immunocompromised patients are at high risk of invasive fungal infections (IFI), in particular those with haematological malignancies undergoing remission-induction chemotherapy for acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) and recipients of allogeneic haematopoietic stem cell transplants (HSCT). Despite the development of new treatment options in the past decades, IFI remains a concern due to substantial morbidity and mortality in these patient populations. In addition, the increasing use of new immune modulating drugs in cancer therapy has opened an entirely new spectrum of at risk periods. Since the last edition of antifungal prophylaxis recommendations of the German Society for Haematology and Medical Oncology in 2014, seven clinical trials regarding antifungal prophylaxis in patients with haematological malignancies have been published, comprising 1227 patients. This update assesses the impact of this additional evidence and effective revisions. Our key recommendations are the following: prophylaxis should be performed with posaconazole delayed release tablets during remission induction chemotherapy for AML and MDS (AI). Posaconazole iv can be used when the oral route is contraindicated or not feasible. Intravenous liposomal amphotericin B did not significantly decrease IFI rates in acute lymphoblastic leukaemia (ALL) patients during induction chemotherapy, and there is poor evidence to recommend it for prophylaxis in these patients (CI). Despite substantial risk of IFI, we cannot provide a stronger recommendation for these patients. There is poor evidence regarding voriconazole prophylaxis in patients with neutropenia (CII). Therapeutic drug monitoring TDM should be performed within 2 to 5 days of initiating voriconazole prophylaxis and should be repeated in case of suspicious adverse events or of dose changes of interacting drugs (BIItu). General TDM during posaconazole prophylaxis is not recommended (CIItu), but may be helpful in cases of clinical failure such as breakthrough IFI for verification of compliance or absorption. 
650 4 |a Amphotericin B 
650 4 |a Antifungal prophylaxis 
650 4 |a Fluconazole 
650 4 |a Invasive fungal infection 
650 4 |a Isavuconazole 
650 4 |a Itraconazole 
650 4 |a Liposomal 
650 4 |a Posaconazole 
700 1 |a Buchheidt, Dieter  |d 1955-  |e VerfasserIn  |0 (DE-588)1028287461  |0 (DE-627)730538621  |0 (DE-576)375787380  |4 aut 
700 1 |a Giesen, Nicola  |d 1983-  |e VerfasserIn  |0 (DE-588)141844272  |0 (DE-627)631828524  |0 (DE-576)32643657X  |4 aut 
773 0 8 |i Enthalten in  |t Annals of hematology  |d Berlin : Springer, 1991  |g 97(2018), 2, Seite 197-207  |h Online-Ressource  |w (DE-627)253389852  |w (DE-600)1458429-3  |w (DE-576)072283157  |x 1432-0584  |7 nnas  |a Primary prophylaxis of invasive fungal infections in patients with haematological malignancies 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO) 
773 1 8 |g volume:97  |g year:2018  |g number:2  |g pages:197-207  |g extent:11  |a Primary prophylaxis of invasive fungal infections in patients with haematological malignancies 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO) 
856 4 0 |u http://dx.doi.org/10.1007/s00277-017-3196-2  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://doi.org/10.1007/s00277-017-3196-2  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20181123 
993 |a Article 
994 |a 2018 
998 |g 141844272  |a Giesen, Nicola  |m 141844272:Giesen, Nicola  |d 910000  |d 910100  |e 910000PG141844272  |e 910100PG141844272  |k 0/910000/  |k 1/910000/910100/  |p 11 
998 |g 1028287461  |a Buchheidt, Dieter  |m 1028287461:Buchheidt, Dieter  |d 60000  |d 61200  |e 60000PB1028287461  |e 61200PB1028287461  |k 0/60000/  |k 1/60000/61200/  |p 5 
999 |a KXP-PPN1584374500  |e 3033717047 
BIB |a Y 
SER |a journal 
JSO |a {"note":["Published online 7 December 2017","Gesehen am 23.11.2018"],"recId":"1584374500","name":{"displayForm":["Sibylle C. Mellinghoff, Jens Panse, Nael Alakel, Gerhard Behre, Dieter Buchheidt, Maximilian Christopeit, Justin Hasenkamp, Michael Kiehl, Michael Koldehoff, Stefan W. Krause, Nicola Lehners, Marie von Lilienfeld-Toal, Annika Y. Löhnert, Georg Maschmeyer, Daniel Teschner, Andrew J. Ullmann, Olaf Penack, Markus Ruhnke, Karin Mayer, Helmut Ostermann, Hans-H. Wolf, Oliver A. Cornely"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"eki":["1584374500"],"doi":["10.1007/s00277-017-3196-2"]},"language":["eng"],"origin":[{"dateIssuedDisp":"2018","dateIssuedKey":"2018"}],"relHost":[{"part":{"issue":"2","extent":"11","year":"2018","text":"97(2018), 2, Seite 197-207","pages":"197-207","volume":"97"},"physDesc":[{"extent":"Online-Ressource"}],"titleAlt":[{"title":"Hematology"}],"title":[{"title_sort":"Annals of hematology","subtitle":"organ of: Gesellschaft für Thrombose- und Hämostaseforschung, DGHO, Deutsche Gesellschaft für Hämatologie und Onkologie e.V., ÖGHO, Österreichische Gesellschaft für Hämatologie und Onkologie","title":"Annals of hematology"}],"id":{"zdb":["1458429-3"],"issn":["1432-0584"],"eki":["253389852"]},"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"origin":[{"dateIssuedDisp":"1991-","publisherPlace":"Berlin ; Heidelberg ; New York","dateIssuedKey":"1991","publisher":"Springer"}],"note":["Gesehen am 24.04.2025","Fortsetzung der Druck-Ausgabe","Ungezählte Beil. ab 80.2001: Supplement"],"pubHistory":["62, 1 (Februrary 1991)-"],"recId":"253389852","disp":"Primary prophylaxis of invasive fungal infections in patients with haematological malignancies 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)Annals of hematology"}],"physDesc":[{"extent":"11 S."}],"person":[{"role":"aut","family":"Mellinghoff","display":"Mellinghoff, Sibylle Christiane","given":"Sibylle Christiane"},{"role":"aut","given":"Dieter","display":"Buchheidt, Dieter","family":"Buchheidt"},{"role":"aut","display":"Giesen, Nicola","family":"Giesen","given":"Nicola"}],"title":[{"subtitle":"2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","title":"Primary prophylaxis of invasive fungal infections in patients with haematological malignancies","title_sort":"Primary prophylaxis of invasive fungal infections in patients with haematological malignancies"}]} 
SRT |a MELLINGHOFPRIMARYPRO2018